Topic: [ANN][ICO] BioNT - Advanced Pharma Intelligence - 20% Bonus first 2 weeks - page 3. (Read 2336 times)

Interesting project. Already part of signature campaign.

Are you really based in the Crypto Valley of Zug, or as many Crypto Companies have only a PO Box there?

I wish you success. Good luck.

Hi NokasKili

Obrigado. Bounty campaign is live: https://bitcointalksearch.org/topic/m.21771855

Abraços

Congratulations for this project!
If by any change you required a professional Portuguese translator with experience and quality to support with ANN, Bounty, WHITE PAPER or websites, please kindly PM!
Thank you and all the success for the project!

Nice project and nice team. I like the idea of this a lot,
   The team and the whitepaper also looks solid.
Maybe i'll join this 

Good luck guys and signing up for signature campaign...

Get your facts straight first mate, it's either by 2020 or 2022 it will go as high as $2.2 trillion, which is it? by taking %50 of the funds for development

You are literally selling $1.1 trillion potential investment just to develop a software a system without even being endorsed by one single manufacturer

Of any drugs, that's brilliant mate. what made you think that a giant industry such as medicine and drugs is interested on becoming a decentralized and

Chaotic ecosystem like all the cryptocurrencies are now? who is gonna force the companies in this business to comply with your rules and who will do

The enforcing with what kind of authority? lets think of another way to fuck people over with your bullshit ICOs, what happened to decentralized gov

Or gov as a service, or even a better one why not build a decentralized zoo?

Having worked for a large american pharmacy chain for the last 5 years I have seen the price that patients are responsible to pay for medications is astronomical. I know there is going to be profit in this venture, as long as the funds are handled right and the management keeps there focus on the end game.  Something I am hearing less and less about, because 90 percent of people on this forum are profit hungry to say the least, but with your project needs to be addressed is weather there will be any financial benefit to the patients. Is this going to drive prices down for them and still drive profits up. Any pharma that can put out a life changing drug will become rich, all they have to do is step on the backs of those that are desperate for the benefit that drug provides. I saw it day in and day out and heard story day after day of how it would ,often times be a choice for the patient of wether they bought meds or food or had heat in the winter, etc. Don't get me wrong I know that drugs cost millions of dollars to make and brands take more millions to get in peoples heads and mouths. But if that means taking a person dying from cancer and squeezing them for every dollar they have to give then 2 more years in poverty so that some CEO can have another Bentley, that should be illegal.  I can only get behind a company that's out to produce the best medication and get it to the patient at an affordable cost. Where does your company stand or have you even though about how if successful you going to pay back the people who really finance your grow, the patient.  Sorry if I come off stand offish against your company because I'm not. Every thing i've read leads me to believe you are going to do some great things. I am just very passionate about what patients have to do some times to get there meds, having also worked as a nurse, i do know how life changing the right meds can be. I will most definitely be following your project and will surely purchase some of your coins unfortunately it wont be a lot or even the amount id like but since Im between jobs right now funds are tight but they are never to tight to put something into projects that have potential and that align with your beliefs. If there is anything you think i can do to further your success don't hesitate to let me know. wishing you all the best successes 

Tremendous deal.Good source of buying token.

The revenue buyback is locked for 25 years.

The rational is to drive token value ( remember profit can be adjusted, not revenue )

The project is going through FINMA approval (this is the Swiss financial regulator) this will be the 1st ICO to file a prospectus - hence the some what slow start.  We also have road shows planned in London, Geneva, Zurich, Singapore and HongKong. We will post the dates, times and venues.

We will have live demos of the beta version of the applications, and Q&A - we are very excited and welcome your support.

Wow! 50% of revenue buyback of tokens! They're definitely serious in re-investing their money back into the value of the tokens.
I work in the biotech/pharma industry and they definitely know what they're talking about.

I will definitely invest. Am new to this but this looks solid to me...

New projects who manage by irfan pak, i am interested. i thinks this ICO very promosing and concept or details very perfectly.

I want to see this ICO succes. good luck.
regards from me : brokens

Seems almost too good to be true... watching this closely.

Arabic And Urdu Translation Reserved..
pm

This is interesting plan to use the 50% of the revenue as buy back option how long it will continue to use this option. I'm pretty sure this will bring real value to this token so all holders will make nice profit. Overall this project has nice plan for brighter future I will keep following this.

Unsold tokens will bel locked for 5 years.  Each year 50% of REVENUE (as opposed to profit) will be used to buy back tokens which will be destroyed.

There are 3 assets - applications; 1:drug pricing, 2:drug and pipeline forecasting and the 3: trading platform, the projected annual revenue of these applicatons is expected to exceed USD +$125(m) on an annual basis.  This is the driver for the valuation.

The bounty campaign will be announced shortly, look forward to your feedback and questions

good project sir and i will wait bounty from this project nantik will project project will be implemented bounty and i am sure this will be great sks karna dev from peoject this is very experienced

Who owns the unsold tokens? as you said ¨unsold tokens¨ will be held in ¨Treasury¨ I assume it belongs to the company. So no tokens will be burned, and 300 tokens per 1 ETH, total 140M tokens, making the evaluation of the company of 140M! that's a high estimate of the value yourself. If my calculation is correct.
There is a great danger that tokens are centralized.

Our Solution
- Single global drug pricing platform

It will be a reseller, but will also produce medicines with partnerships?

This looks pretty exciting, I have not seen many pharma based systems. Q: Will the stock trading platform be available to the public or only traders and bankers?

---

---

---

Summary

Structure and platform
Incorporation Status:   ADVANCED PHARMA INTELLIGENCE GMBH
Location: ZUG, SWITZERLAND
Team   : TRANSPARENT IDENTITIES
Technical White Paper: TECHNICAL AND PLATFORM
Beta Version: DRUG PRICING BETA VERSION
Proof of concept: DRUG FORECASTING PLATFORM
Mobile app: PROJECT X ? TO BE PATENTED
Trading platform   : ARCHITECURE PLAN

Token Description
Token name: BioNT
Allocation:   140,000,000 TOKENS
Token Sale period: 21.08.2017 08:00PM UTC TILL 23.10.2017 08:00PM UTC
Unsold Tokens:   SUBJECT TO LOCKUP OF 5 YEARS
Bonus Weeks 1 to 4:   1ST+2ND WEEK 20%, 3RD WEEK 15%, 4TH WEEK 10%, 5TH WEEK 5%
Week 6 - 9   : FINISHING OCTOBER 23, 2017, NO BONUS TOKENS

---

Introduction

Industry Background

-   7,000 drugs in development
-   Industry set to grow from $800 Billion to $1.2 Trillion globally by 2020
-   Generic, Pharmaceutical and Biotech remain in the top ten most profitable industries in the world
-   With so many drugs in discovery, how do you bet on the break through, and the financially profitable ones?

The global Pharma and Biotech Industry ranks high among the most profitable industries in the world.  The current market is estimated to grow from $800 Billion USD to $1.2 Trillion by 2022.  The market cap of the top 100 pharmaceutical companies is $2.2 Trillion dollars.

Problems with current pharma and biotech drug pricing and financial forecasting
McKinsey confirms pharma forecasts fragile, the extent of imprecision is truly remarkable.

1.   Commercially driven forecasts to secure budgets and investment
2.   The internal silo impact reducing efficiency and accuracy
3.   Lack of integration of pricing & reimbursement assumptions and the probability of pricing & reimbursement outcomes
4.   Not using common global language across entire organization
5.   Limited capabilities within the organization
6.   Ignoring impact of data sources & external events, lack of catalogued references and assumptions

To improve outcomes and capabilities, companies need to integrate real-time accounts of their judgments, underlying assumptions, data sources, external events including trends in reimbursement.

Key drivers behind forecast failures are poor assumptions
There's no chance that the iPhone will gain any significant market share?  Steve Ballmer, Microsoft 2007

New product forecasting (NPF) is inherently difficult, usually inaccurate, and past analogues do not incorporate emerging trends. ?It's not what we know that leads to poor forecasting outcomes; its what we knew, ignored and didn't communicate?  Global biotech forecaster, 2014

Our Solution and Development Roadmap to Drug Discovery

-   Global Drug Pricing
-   Global Disease and Epidemiology
-   Clinical Trial Outcomes and Approvals
-   Advanced Pharma Intel Algorithm
-   Market and Drug Performance


The global drug pricing platform is designed to retrieve drug prices from global disparate sources.  Sources are both public/government and private sources.  The initial focus will be Oncology and Orphan diseases, paving the way for price setting and trends for new combination therapies.

Epidemiology data bank will store patient treatment pathways for key diseases, the data bank will also be populated with patient numbers to link new molecules to market potential.

Tracking both historical and upcoming outcomes and approvals will enable the platform to predict and report the sensitivity analysis. The key data blocks linked with historical data, will allow Advanced Pharma Intelligence not only the ability to deliver analysis to front end clients, but also the algorithm to predict outcomes based on Phase I and Phase II outcomes data.   


Who we are, and what we do
-   Seasoned team of industry experts based in Zug, Switzerland
-   Combining industry, pricing, software and trading knowledge
-   Translate global data into a single non-biased fact-based platform
-   Seek and identify the highest profitable molecules in clinical development

The Problem
-   There are 7,000 drugs in development, and 70% of those will be first in class
-   Only 2 out of 10 drugs match or exceed R&D investment4
-   Evaluate Pharma lowers projections for next 5 years by $390 billion mainly due to pricing pressure
-   Forecasting is becoming more and more complex due to bio-markers and orphan indications
-   Trading and stock price volatility has been increasing as a result

Our Solution
-   Single global drug pricing platform
-   Disease and epidemiology database
-   Drug forecasting platform
-   Integrated drug pricing and forecasting system through Blockchain
-   Securities trading signals

---

Our Roadmap

-   Development of scalable drug pricing system
-   Commercialization of the drug pricing system
-   Development and commercialization of the drug forecasting system
-   Development of the X-App
-   Development of the securities trading signals



The BioNT Token

-   140,000,000 BioNT Tokens
-   5-year lock up of unsold tokens
-   50% of annual software revenues for token buy back
a.   Those tokens will be deleted after buyback


Development Road Map
The development and commercialization of the three core projects will be subject to the level of funding secured.  The timeline outlined for development and delivery seeks to maximize both development and commercialization. 

The X-APP will be detailed post development and prior to commercialization. The APP will provide a hub to link and retrieve global data for the platforms described above.


Development Phasing
1   Develop & Commercialize the Drug Pricing Platform - 3 months
2   Develop Drug Forecasting Platform - 4-8 months
X   Develop APP-X Global Data Sourcing App - TBC
3   Develop Trading Platform - 8-16 months

---

Investment Allocation
 
             
- Development of trading Platform - 25%
- Development of Drug Forecasting Platform - 20%
- Global Marketing & Sales Phase 1 - 10%
- Global Marketing & Sales Phase 2 - 10%
- Merge Pricing and Forecasting Platform - 10%
- Enhancement of, and Commercialization Beta Pricing Platform - 10%
- Team Allocation - 10%
- Legal - 5%

---

BioNT Token

Token ICO starting 21-08-2017, at 08.08pm UTC, until sold out or till end of ICO period.

- 1st + 2nd weeks 20% additional tokens
- 3rd week 15% additional tokens
- 4th week 10% additional tokens
- 5th week 5% additional tokens
- 6th/9th week, finishing 23-10-2017, at 08.08pm UTC, no bonus tokens

Token Name: BioNT
Fixed Price: 300 BioNT per ETH
Issuing Entity: Advanced Pharma Intelligence GmbH
Jurisdiction of Issuance: Switzerland
Time to Issuance: Tokens are issued immediately to your Ether Wallet were you hold your private key. However, Tokens will have a transfer freeze until the tokens are listed on exchanges.

If any tokens left after that period, these ¨unsold tokens¨ will be held in ¨Treasury¨ of the Advanced Pharma Intelligence GmbH, available for a sale in secondary market, but with a lockup of 1825 days, basically five years (5*365), hard coded in the smart contract.

The number of tokens are capped, 140 million, (the maximum amount raised does depend on the additional bonus tokens in the first few weeks of the offering, this is automatically done in the smart contract settings too).

126 million tokens available for the crowdsale campaign.
14 million tokens, with a 6 month lock up, are reserved for Advanced Intelligence GmbH and founders team.

Advanced Pharma Intelligence GmbH develops and enhances its systems (existing and planned new systems) and business development (commercialization of existing beta tested and to be developed ones).

Advanced Pharma Intelligence GmbH will buy in the secondary market, both on the exchanges as well as in direct deals with participants at a price not exceeding the then market price, a minimum of 50%of the software revenues each year, for 25 years, those tokens will be deleted (¨irreversibly moved to trash¨) after buyback. This will be done in the second month after the year was finished, i.e. February 2018/2041. Announcement of how many tokens at what average price have been bought back will follow one month after the completion of those buybacks.

In February/April 2042, buyback in the open market will be done for a three-month period, and the total sum of buybacks will be divided by the number of still outstanding/not bought back tokens (possibly including any tokens that are still in the Treasury of Advanced Pharma Intelligence GmbH and haven't been sold in a secondary offering). If any tokens haven't been offered for sale at the secondary market, management of Advanced Pharma Intelligence GmbH will donate the remainder of the monies to a good cause of their choice (one or more not-for profit charitable organizations, e.g. World Cancer Research Fund, Red Cross).
In exceptional cases, in order to provide the most risk averse features, we may upgrade the smart contract code and update and transparently send the new valid token, e.g. in case the exchanges, where we'd like to list, demand such.

Gas limit is responsibility of the sender/contributor.

In case the cap (126 million tokens for sale in crowdsale) is reached, excess payments will be rejected and repaid.

---